ERBB2 and breast carcinoma: Another compound, AUY922, showed a 22.0% overall response rate and 48.8% of the patients had stable disease among the 41 enrolled patients in combination with trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer that had been previously treated with chemotherapy and anti-HER2 therapy (NCT01271920) [217].